ArticleScience translational medicine2025
A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma.
Abstract readClinical Trial, Phase I
In one paragraph
Article in Science translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Final report on North Central Cancer Treatment Group N0877 (alliance): A phase II randomized, placebo-controlled trial of chemoradiotherapy with or without dasatinib for glioblastoma.Neuro-oncology · 2025Trial
- Natural and Synthetic Compounds, Swords for Glioblastoma Therapy: From Tumor to Its Microenvironment.International journal of molecular sciences · 2026Review
- Exploring the landscape of targetable alterations in patients with glioblastoma.Nature reviews. Clinical oncology · 2026Review
- Cystic glioblastoma is associated with alterations of KDR and the Rb pathway: a single-center retrospective analysis.Acta neuropathologica communications · 2026Article
- The evolving global landscape of first-in-class oncology drug innovation.Signal transduction and targeted therapy · 2026Review
- Molecularly Targeted Therapies in Oncology: Mechanisms, Resistance, and Combination Strategies.Molecules (Basel, Switzerland) · 2026Review
- Targeting TRIM25 as a therapeutic strategy to enhance ferroptosis in glioblastoma cells.Journal of nanobiotechnology · 2026Article
- p53 Pathway-Targeted Therapeutic Strategies in Glioblastoma: A CNS-Specific Framework Integrating Therapeutic Resistance, Molecular Stratification, CNS Pharmacology, and Clinical Translation.Drug design, development and therapy · 2026Review
- Multidimensional tumor heterogeneity and its role in therapeutic resistance.Frontiers in immunology · 2026Review
- Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.Neuro-oncology · 2025Review
- Glioma drug development benefits from emerging phase 0 and window-of-opportunity trial paradigm.Cell communication and signaling : CCS · 2025Review
- Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH-Wild-type Glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts.Neuro-oncology advancesArticle
- A phase 0 clinical trial to evaluate the neuropharmacological profile of posaconazole for glioblastoma.Neuro-oncology advancesArticle
Corrections and comments
- Update of
Authors and funding
43 authors.
Veronica RendoDepartment of Medical Oncology and Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0002-2983-4020
Eudocia Q LeeDepartment of Medical Oncology and Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0003-3355-5179
Connor BossiDepartment of Pathology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0003-4922-2723
Nicholas KhuuDepartment of Medical Oncology and Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0009-0001-9967-1538
Michelle A RudekSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.ORCID 0000-0001-5739-6868
Sangita PalDepartment of Medical Oncology and Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0002-4892-841X
Narmen AzazmehDepartment of Medical Oncology and Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0002-7897-8274
Rumana RashidDepartment of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.ORCID 0000-0001-6986-7209
Jia-Ren LinLaboratory of Systems Pharmacology, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0003-4702-7705
Margaret CusickDepartment of Pathology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Abigail R N ReynoldsDepartment of Medical Oncology and Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0003-4120-3704
Auriole C R FassinouDepartment of Medical Oncology and Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0009-0000-9385-5486
Georges AyoubDepartment of Pathology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0002-1694-6779
Seth MalinowskiDepartment of Pathology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Emily LapinskasDepartment of Pathology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0001-9860-3544
William PisanoDepartment of Pathology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0001-7428-2344
John JeangDepartment of Medical Oncology and Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Sylwia A StopkaDepartment of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0003-3761-6899
Michael S ReganDepartment of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0001-5252-2829
Johan SpetzDepartment of Medical Radiation Sciences, Sahlgrenska Cancer Center, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, 405 30 Gothenburg, Sweden.ORCID 0000-0002-5216-9786
Arati DesaiDivision of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0002-4849-4703
Frank LiebermanDepartment of Neurology, University of Pittsburgh, Pittsburgh, PA 15213, USA.ORCID 0000-0003-2577-3336
Kamalakannan PalanichamyDepartment of Neurology, Wake Forest University, Winston-Salem, NC 27157, USA.ORCID 0000-0002-3216-7812
Joy D FisherSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.
Kristine PeltonDepartment of Pathology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Raymond Y HuangDepartment of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0001-7661-797X
Kristopher A SarosiekDepartment of Medical Oncology and Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0002-4618-5085
Louis B NaborsDepartment of Neurology, University of Alabama at Birmingham, Birmingham, AL 35233, USA.ORCID 0000-0001-5926-2230
Matthias HoldhoffSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.
Neeraja DandaDivision of Hematology, Departments of Medicine and Oncology, Montefiore Medical Center, New York, NY 10467, USA.
Roy StrowdDepartment of Neurology, Wake Forest University, Winston-Salem, NC 27157, USA.ORCID 0000-0001-6651-5267
Serena DesideriSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.ORCID 0009-0007-0682-6080
Tobias WalbertDepartment of Neurology and Neurosurgery Henry Ford Health, Department of Neurology, Wayne State University and Michigan State University, Detroit, MI 48201, USA.ORCID 0000-0003-0667-8106
Xiaobu YeSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.ORCID 0009-0005-5356-4840
Arnab ChakravartiDepartment of Radiation Oncology, Ohio State University College of Medicine, Columbus, OH 43210-1228, USA.
Peter K SorgerLaboratory of Systems Pharmacology, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-3364-1838
Sandro SantagataDepartment of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.ORCID 0000-0002-7528-9668
Nathalie Y R AgarDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0003-3149-3146
Stuart A GrossmanSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.ORCID 0000-0002-3726-7679
Brian M AlexanderDepartment of Radiation Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0003-3903-9175
Patrick Y WenDepartment of Medical Oncology and Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0002-0774-7700
Keith L LigonHarvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-7733-600X
Rameen BeroukhimDepartment of Medical Oncology and Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0001-6303-3609
Funding
Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI ALAN KEITH MEEKER · 1985 to 2026
$208.6MQAQC Johns Hopkins Institute for Clinical and Translational ResearchUL1TR003098 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2019 to 2023
$57.7MThe internship in Biomedical Research, Informatics, and Computer Science (iBRIC): Biomedical Informatics and Data Science research experiences for students from Minority Serving InstitutionsT15LM007059 · NLM · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HARRY S HOCHHEISER · 1987 to 2026
$23.9MTRD 3 - Enabling Technologies for Intraprocedural GuidanceP41EB028741 · NIBIB · BRIGHAM AND WOMEN'S HOSPITAL · PI Oliver Jonas · 2021 to 2026
$10.7MTrans Network ProjectU54CA210180 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI SARKARIA, JANN N., WHITE, FOREST M · 2016 to 2020
$10.2MAdult Brain Tumor Consortium (ABTC)UM1CA137443 · NCI · JOHNS HOPKINS UNIVERSITY · PI GROSSMAN, STUART A · 2014 to 2020
$9.7MGenetic evolution of glioblastomas during radiation and temozolomide therapyR01CA188228 · NCI · DANA-FARBER CANCER INST · PI BEROUKHIM, RAMEEN, CHAKRAVARTI, ARNAB · 2015 to 2025
$6.9MTargeting the neuronal microenvironment in glioblastomaU19CA264504 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI MICHAEL J ECK · 2021 to 2026
$6.4MSynthetic lethalities to cell cycle disruption in gliomaR01CA262462 · NCI · DANA-FARBER CANCER INST · PI RAMEEN BEROUKHIM, KEITH LLOYD LIGON · 2022 to 2026
$3.3MCharacterizing TP53 and PPM1D mutations as resistance drivers to radiation therapy in Diffuse Intrinsic Pontine GliomasR01CA219943 · NCI · BROAD INSTITUTE, INC. · PI BEROUKHIM, RAMEEN, LIGON, KEITH LLOYD · 2017 to 2021
$2.5MAdvancing technologies for the collection and analysis of high dimensional immunoprofiles and tumor imagesR50CA274277 · NCI · HARVARD MEDICAL SCHOOL · PI Jia-Ren Lin · 2022 to 2026
$879kUPLC with Tandem MS for Sensitive Quantitative Analysis of Small MoleculesS10RR026824 · NCRR · JOHNS HOPKINS UNIVERSITY · PI RUDEK, MICHELLE A · 2010 to 2010
$429kNCATS NIH HHS UL1 TR003098NCI NIH HHS P30 CA006973NCI NIH HHS R01 CA188228NCI NIH HHS R01 CA219943NCI NIH HHS R01 CA262462NCI NIH HHS R50 CA274277NCI NIH HHS U19 CA264504NCI NIH HHS U54 CA210180NCI NIH HHS UM1 CA137443NCRR NIH HHS S10 RR026824NIBIB NIH HHS P41 EB028741NLM NIH HHS T15 LM007059
Abstract
Inhibitors of murine double minute homolog 2 (MDM2) represent a promising therapeutic approach for the treatment of
Indexed as
Brain NeoplasmsDrug Resistance, NeoplasmGlioblastomaNeoplasm Recurrence, LocalAdultAgedCell Line, TumorFemaleHumansMaleMiddle AgedProto-Oncogene Proteins c-mdm2Tumor Suppressor Protein p53Proto-Oncogene Proteins c-mdm2Tumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.